Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Starting soon · Phase 4

Conditions studied: Diabete Type 2

In brief

The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Key facts

Study ID

NCT07365358

Run by

Chong Kun Dang Pharmaceutical

People needed

200

Starts

2026-03-01

Expected to finish

2027-08-01

Last updated by the study team

2026-01-26

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Over 19 years old
• Type 2 diabetes mellitus
• Patient who has been taking oral hypoglycemic agents for over 8 weeks
• Agreement with written informed consent

You may not qualify if…

• Type 1 diabetes mellitus or secondary diabetes mellitus
• Patients with complications of severe diabetes such as proliferative diabetic retinopathy
• Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
• Patients with abnormal laboratory test results according to the protocol
• Continuous or non-continuous treatment with insulin for over 7 days within 12 weeks prior to screening
• History of treatment with corticosteroids within 4 weeks prior to screening

Where it is running

• Kyung Hee University Hospital at Gangdong — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.